Canaccord Genuity Group Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective cut by research analysts at Canaccord Genuity Group from $141.00 to $140.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 56.32% from the company’s current price.

A number of other equities research analysts have also recently issued reports on RYTM. HC Wainwright lowered their target price on shares of Rhythm Pharmaceuticals from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Monday. Guggenheim lifted their price target on Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Needham & Company LLC decreased their price objective on Rhythm Pharmaceuticals from $148.00 to $139.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Wall Street Zen cut Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Stifel Nicolaus set a $131.00 target price on Rhythm Pharmaceuticals in a research note on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $132.07.

Rhythm Pharmaceuticals Stock Down 5.7%

Rhythm Pharmaceuticals stock opened at $89.56 on Monday. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $122.20. The firm has a 50 day moving average price of $103.08 and a 200-day moving average price of $103.51. The company has a market capitalization of $6.12 billion, a P/E ratio of -28.80 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The company had revenue of $57.25 million during the quarter, compared to the consensus estimate of $56.16 million. During the same quarter in the prior year, the company earned ($0.72) EPS. The firm’s quarterly revenue was up 36.9% compared to the same quarter last year. Equities analysts expect that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insider Activity at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider owned 20,814 shares of the company’s stock, valued at approximately $2,310,354. This trade represents a 13.86% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 25,003 shares of company stock worth $2,589,015. 6.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its holdings in shares of Rhythm Pharmaceuticals by 148.2% during the 1st quarter. AQR Capital Management LLC now owns 39,363 shares of the company’s stock worth $2,085,000 after acquiring an additional 23,506 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Rhythm Pharmaceuticals by 6.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,282 shares of the company’s stock worth $1,874,000 after purchasing an additional 2,126 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Rhythm Pharmaceuticals by 3.0% during the 2nd quarter. Teacher Retirement System of Texas now owns 12,772 shares of the company’s stock valued at $807,000 after acquiring an additional 368 shares during the period. Freestone Capital Holdings LLC purchased a new stake in Rhythm Pharmaceuticals in the second quarter worth about $234,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Rhythm Pharmaceuticals by 25.6% during the second quarter. Bank of New York Mellon Corp now owns 184,109 shares of the company’s stock valued at $11,634,000 after purchasing an additional 37,524 shares in the last quarter.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Price target raised to $176, a sizable bullish revision that supports upside for RYTM. Price Target Raised to $176
• Positive Sentiment: Price target raised to $143 by another analyst — another explicit vote of confidence that could buoy sentiment. Price Target Raised to $143
• Positive Sentiment: HC Wainwright published a bullish FY‑2027 EPS forecast of $1.06 and reiterates a “Buy” rating with a $110 target — the EPS call is particularly notable because it contrasts sharply with the street consensus, implying a materially improved outlook if realized. MarketBeat RYTM Coverage
• Neutral Sentiment: Canaccord set a $140 price target (a small trim from $141) and maintains a buy stance — modestly positive but largely neutral given the tiny cut. Canaccord $140 Target
• Neutral Sentiment: Yahoo Finance published a valuation review of RYTM after the recent pullback — useful context for investors assessing whether current weakness creates a buying opportunity or signals overvaluation. Valuation Article
• Negative Sentiment: HC Wainwright lowered its price target from $125 to $110 in a separate note — a downward revision that may be cited by sellers despite the firm’s continued Buy rating and optimistic EPS estimate. HC Wainwright Price Target Cut to $110

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.